Literature DB >> 25653708

Aggravation of hepatopulmonary syndrome after sildenafil treatment in a patient with coexisting portopulmonary hypertension.

Seungmin Chung1, Kyungho Lee2, Sung-A Chang1, Duk-Kyung Kim1.   

Abstract

Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPHTN) are complications of portal hypertension and cirrhosis. Their pathophysiological mechanisms clearly differ. HPS is characterized by a defect in arterial oxygenation induced by pulmonary vascular dilatation. In contrast, PPHTN is predominantly due to excessive pulmonary vasoconstriction and vascular remodeling, but is rarely associated with hypoxia. We report a case of a patient who had both HPS and PPHTN at the time of presentation. HPS was aggravated after sildenafil administration for the treatment of PPHTN. We demonstrated increased amount of intrapulmonay shunt after sildenafil challenge by using agitated saline contrast transthoracic echocardiography.

Entities:  

Keywords:  Hepatopulmonary syndrome; Pulmonary arterial hypertension; Sildenafil

Year:  2015        PMID: 25653708      PMCID: PMC4310984          DOI: 10.4070/kcj.2015.45.1.77

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


  16 in total

Review 1.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

2.  Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension.

Authors:  Pablo F Castro; Douglas Greig; Hugo E Verdejo; Iván Godoy; Samuel Córdova; Marcela P Ferrada; Robert C Bourge
Journal:  Thorax       Date:  2011-02-02       Impact factor: 9.139

3.  Sildenafil treatment for portopulmonary hypertension.

Authors:  F Reichenberger; R Voswinckel; E Steveling; B Enke; A Kreckel; H Olschewski; F Grimminger; W Seeger; H A Ghofrani
Journal:  Eur Respir J       Date:  2006-06-28       Impact factor: 16.671

Review 4.  The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension.

Authors:  Dongmin Shao; John E S Park; Stephen J Wort
Journal:  Pharmacol Res       Date:  2011-03-16       Impact factor: 7.658

5.  Sildenafil modulates hemodynamics and pulmonary gas exchange.

Authors:  A Kleinsasser; A Loeckinger; C Hoermann; F Puehringer; N Mutz; G Bartsch; K H Lindner
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

6.  Intrapulmonary arteriovenous shunt: diagnosis by saline contrast bubbles in the pulmonary veins.

Authors:  Anuradha Gudavalli; Vijay G Kalaria; Xucai Chen; Karl Q Schwarz
Journal:  J Am Soc Echocardiogr       Date:  2002-09       Impact factor: 5.251

7.  Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.

Authors:  Michael S Gough; R James White
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

Review 8.  Portopulmonary hypertension and hepatopulmonary syndrome.

Authors:  Marius M Hoeper; Michael J Krowka; Christian P Strassburg
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

9.  Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats.

Authors:  Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; David M Pollock; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02-05       Impact factor: 4.052

Review 10.  Prostacyclin and its analogues in the treatment of pulmonary hypertension.

Authors:  Horst Olschewski; Frank Rose; Ralph Schermuly; H Ardeschir Ghofrani; Beate Enke; Andrea Olschewski; Werner Seeger
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  1 in total

1.  Mechanical characteristics of the pulmonary artery in beagle dogs with hepatopulmonary syndrome and portopulmonary hypertension.

Authors:  Guozhen Yan; Junfeng He; Yueli Yu; Yang Liu; Yanfen Yuan; Zhiyong Guo
Journal:  Biomed Rep       Date:  2015-10-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.